

made in exercise performance between COPD and Healthy controls (HC), during aerobic training and more importantly limited data exists on the rates of detraining between the groups.


**Methods** This study measures sub-maximal and maximal performance in response to an aerobic training programme and to a period of detraining.

COPD and HC undertook 8 weeks of supervised cycling exercise training three times a week. There consequently followed a 4 week period of detraining, and resumption of pre cycling habitual activity (not engaging in regular exercise). A symptom limited incremental cycle (ramp protocol) and constant work rate (sub-maximal/ endurance) cardiopulmonary exercise tests (CPET) were performed at baseline, after 4 and 8 weeks of training and after detraining. Cycling training intensity and CPET endurance work were equivalent to 65% of the Work (in Watts (W)) at VO<sub>2</sub> Peak during the baseline CPET ramp test. Training intensity was re-set if there was any improvement during the 4-week CPET ramp test. **Results** 10 COPD patients (MRC 3, 2 males, age 74 years, FEV<sub>1</sub> 63.5% predicted) and 7 HC (MRC 1, 4 males, age 71 years, FEV<sub>1</sub> 111% predicted) completed the study. COPD group had lower starting training workloads (59.5 vs 121 Watts,  $p < 0.05$ ) compared to HC.

HC showed a significant increase in Peak VO<sub>2</sub> uptake in the ramp but COPD patients only showed an increasing trend. There were however increases in the time achieved during sub-maximal testing in both groups during the 8 week training period. However during detraining, there was relative preservation in the HC but a significant reduction in endurance time in the COPD group.

(All values median, unless stated)

**Conclusion/discussion** Exercising training at moderate intensities showed no changes in maximal performance in COPD groups, compared to HC. However gains in sub-maximal performance were seen in both groups. Training induced gains in sub-maximal performance may be better preserved in HC during detraining, when compared to the COPD groups.



Abstract S57 Figure 1 Sub-Maximal Test

## Latent TB and biomarkers

S58

### PROSPECTIVE HEALTH ECONOMIC EVALUATION OF DIFFERENT RECOMMENDED STRATEGIES FOR TB TESTING IN A CONTEMPORARY HIV POSITIVE COHORT

<sup>1</sup>SJ Capocci, <sup>2</sup>J Sewell, <sup>2</sup>C Smith, <sup>1</sup>I Cropley, <sup>1</sup>S Bhagani, <sup>2</sup>S Morris, <sup>1</sup>M Johnson, <sup>1</sup>MCI Lipman. <sup>1</sup>Royal Free London NHS Foundation Trust, London, UK; <sup>2</sup>University College London, London, UK

10.1136/thoraxjnl-2014-206260.64

**Introduction** The risk of active tuberculosis (TB) disease is estimated to be increased 40-fold in people with HIV (PHIV).

Effective antiretroviral treatment (ART) may reduce this significantly. UK national guidance recommends using blood interferon gamma release assay (IGRA) +/- tuberculin skin testing (TST) for latent TB (LTBI) diagnosis but there are little supporting health economic data. We sought to evaluate the cost-effectiveness of different testing strategies using data from a prospective contemporary cohort.

**Methods** Subjects receiving ambulatory HIV care were recruited by stratified selection within our HIV centre. TST, IGRA (TSpot.TB), frontal chest radiograph (CXR) and single induced sputum for mycobacterial culture were performed. The yield was used to model a screening programme that utilised current UK HIV demographics (Public Health England). Costs were based on the BNF, local costs or published literature (TST £16, IGRA £60, CXR £50, induced sputum £42, treatment for latent and active TB £786 and £7619 respectively). Uptake and LTBI treatment efficacy were both estimated at 65%. We assumed a lifetime reactivation rate with TST+/IGRA+ of 10% and TST+/IGRA- of 2%; and that all those with evidence of LTBI would be given treatment.

**Results** Over 13 months, 211 people were recruited. 26% were female and 26% black African. LTBI rates amongst subjects from sub-Saharan Africa, medium and low TB incidence countries were 8/55 (15%), 2/31 (6%) and 4/125 (3%) respectively. One patient had a persistently indeterminate IGRA. Subclinical TB disease was diagnosed in two (1%) subjects.

Using these data to model TB testing nationally, the British HIV Association (BHIVA) testing algorithm was the most cost-effective with an incremental cost effectiveness ratio (ICER) of £21,475. The NICE algorithm both cost more and prevented fewer cases of active TB (Table 1). More comprehensive strategies were associated with increasing cost.

**Conclusion** Testing only those at highest risk of progression to active TB disease in an HIV population with high ART use was cost-effective, whilst most strategies testing all comers and for active TB cost considerably more than the £20–30,000/QALY gained threshold used in the UK.

S59

### EVALUATING THE CLINICAL UTILITY OF XPERT® MTB/RIF FOR THE DIAGNOSIS AND MANAGEMENT OF TUBERCULOSIS IN A HIGH BURDEN REGION OF THE UK

J Kim, B O'Connor, H Patel, N Perera, M Wiselka, G Woltmann, P Haldar. University of Leicester, Leicester, UK

10.1136/thoraxjnl-2014-206260.65

**Introduction** The importance of Xpert® MTB/RIF (GeneXpert) for the rapid confirmation of tuberculosis (TB) and indicator for drug resistance is now well established for high burden, resource poor countries, with a high prevalence of smear positive pulmonary disease. The phenotype of disease differs significantly in high income countries like the UK with fewer smear positive cases and more extra-pulmonary disease. The role of GX in this setting is unclear.

**Objectives** To evaluate how GeneXpert was being used in local practice and determine factors that influenced test performance.

**Methods** We performed a retrospective analysis of all GeneXpert tested patient samples between October 2011 and April 2014. Out of area sample requests and unprocessed specimens were excluded. Positive GeneXpert results were categorised as very low, low, medium and high. Sensitivity and specificity analyses excluded clinically diagnosed TB without supporting evidence and stratified samples by type and smear status. Statistical analyses were computed on SPSS (v.16).